Teva Pharmaceutical Industries Limited Sponsored ADR Aktie News

Though earnings season is often viewed as the highlight of each quarter, there are a number of other data releases that can tell investors a lot about the health of the stock market. In particular, the filing of Form 13F with the Securities and Exchange Commission is, arguably, one of the most important quarterly data dumps.

Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow quarter to quarter.

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website.

TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Stanley Druckenmiller made a fortune working alongside billionaire George Soros. He ran his own hedge fund for years before closing it in 2010.

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, durat...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Grow...

There's nothing more valuable on Wall Street than data, and investors rarely have to dig to find something that's pertinent to the U.S. economy, the stock market, or their specific portfolio holdings.